Literature DB >> 28872909

Introduction to supplement: the current status of treatment for ALS.

Robert G Miller1, Stanley H Appel2.   

Abstract

ALS is a lethal neurodegenerative disease wherein the diagnosis is often delayed. Our understanding of the pathobiology is slowly expanding, and the number of new genes is rapidly increasing. The development of potential treatments targeting specific mechanisms is beginning to offer hope. Evidence-based treatments and the development of quality measures have raised the standard of care. The current status of treatment for ALS includes one drug riluzole that slows progression modestly, and another drug edaravone that was recently approved by FDA to slow ALS progression. Multidisciplinary clinics and symptomatic treatments ease the burden of ALS and prolong life. An overview of these treatments is provided here.

Entities:  

Keywords:  Treatment; amyotrohpic lateral sclerosis; clinical trials; multidisciplinary clinics; practice parameters; quality measures

Mesh:

Substances:

Year:  2017        PMID: 28872909     DOI: 10.1080/21678421.2017.1361447

Source DB:  PubMed          Journal:  Amyotroph Lateral Scler Frontotemporal Degener        ISSN: 2167-8421            Impact factor:   4.092


  8 in total

1.  Technoeconomic analysis of semicontinuous bioreactor production of biopharmaceuticals in transgenic rice cell suspension cultures.

Authors:  Jasmine M Corbin; Matthew J McNulty; Kantharakorn Macharoen; Karen A McDonald; Somen Nandi
Journal:  Biotechnol Bioeng       Date:  2020-07-14       Impact factor: 4.395

2.  Mecasin treatment in patients with amyotrophic lateral sclerosis: study protocol for a randomized controlled trial.

Authors:  Sungha Kim; Jae Kyoun Kim; Mi Ju Son; Dongwoung Kim; Bongkeun Song; Ilhong Son; Hyung Won Kang; Jongdeok Lee; Sungchul Kim
Journal:  Trials       Date:  2018-04-13       Impact factor: 2.279

3.  MicroRNA expression analysis identifies a subset of downregulated miRNAs in ALS motor neuron progenitors.

Authors:  Mafalda Rizzuti; Giuseppe Filosa; Valentina Melzi; Luca Calandriello; Laura Dioni; Valentina Bollati; Nereo Bresolin; Giacomo Pietro Comi; Silvia Barabino; Monica Nizzardo; Stefania Corti
Journal:  Sci Rep       Date:  2018-07-04       Impact factor: 4.379

Review 4.  CRISPR/Cas9-Mediated Gene Correction to Understand ALS.

Authors:  Yeomin Yun; Yoon Ha
Journal:  Int J Mol Sci       Date:  2020-05-27       Impact factor: 5.923

5.  Geographic Analysis of Motor Neuron Disease Mortality and Heavy Metals Released to Rivers in Spain.

Authors:  Germán Sánchez-Díaz; Francisco Escobar; Hannah Badland; Greta Arias-Merino; Manuel Posada de la Paz; Verónica Alonso-Ferreira
Journal:  Int J Environ Res Public Health       Date:  2018-11-11       Impact factor: 3.390

6.  Multi-Study Proteomic and Bioinformatic Identification of Molecular Overlap between Amyotrophic Lateral Sclerosis (ALS) and Spinal Muscular Atrophy (SMA).

Authors:  Darija Šoltić; Melissa Bowerman; Joanne Stock; Hannah K Shorrock; Thomas H Gillingwater; Heidi R Fuller
Journal:  Brain Sci       Date:  2018-12-04

7.  CuATSM improves motor function and extends survival but is not tolerated at a high dose in SOD1G93A mice with a C57BL/6 background.

Authors:  Jeremy S Lum; Mikayla L Brown; Natalie E Farrawell; Luke McAlary; Diane Ly; Christen G Chisholm; Josh Snow; Kara L Vine; Tim Karl; Fabian Kreilaus; Lachlan E McInnes; Sara Nikseresht; Paul S Donnelly; Peter J Crouch; Justin J Yerbury
Journal:  Sci Rep       Date:  2021-09-29       Impact factor: 4.996

8.  Local and Systemic Humoral Response to Autologous Lineage-Negative Cells Intrathecal Administration in ALS Patients.

Authors:  Bartłomiej Baumert; Anna Sobuś; Monika Gołąb-Janowska; Zofia Ulańczyk; Edyta Paczkowska; Karolina Łuczkowska; Alicja Zawiślak; Sławomir Milczarek; Bogumiła Osękowska; Agnieszka Meller; Karolina Machowska-Sempruch; Agnieszka Wełnicka; Krzysztof Safranow; Przemysław Nowacki; Bogusław Machaliński
Journal:  Int J Mol Sci       Date:  2020-02-06       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.